Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMPRSS4 | Q9NRS4 | 13/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | CRHBP | P24387 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.49 |
| ▸ | P2RX1 | P51575 | 11/20 | 0.48 |
| ▸ | P2RX4 | Q99571 | 4/20 | 0.48 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | CES2 | O00748 | 1/20 | 0.46 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.45 |
| ▸ | IKBKB | O14920 | 1/20 | 0.45 |
| ▸ | CHUK | O15111 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
| ▸ | FLT3 | P36888 | 1/20 | 0.45 |
| ▸ | MYLK | Q15746 | 1/20 | 0.45 |
| ▸ | MAP4K5 | Q9Y4K4 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8393436 | 0.85 | CES2 (0.58) | TMPRSS4NPC1CRHBPRAB9ACRHR2 | |
| Hydrochloric Acid SCHEMBL8393444 | 0.84 | CES2 (0.45) | TMPRSS4NPC1CRHBPRAB9ACRHR2 | |
| SCHEMBL27497007 | 0.84 | CES2 (0.45) | P2RX7CES2KDRKDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL8392414 | 0.82 | JAK2 (0.54) | MEN1KMT2ACES2ALDH1A1HPGD | |
| SCHEMBL24066344 | 0.81 | TMPRSS4 (0.48) | TMPRSS4P2RX1P2RX4P2RX7MEN1 | |
| Hydrochloric Acid SCHEMBL8393384 | 0.81 | NTRK1 (0.47) | TMPRSS4NPC1CRHBPRAB9ACRHR2 | |
| SCHEMBL8116932 | 0.80 | MAPT (0.47) | KDM4E | |
| SCHEMBL21884644 | 0.80 | PPIA (0.50) | TMPRSS4P2RX1P2RX4P2RX7MEN1 | |
| SCHEMBL21884645 | 0.79 | P2RX1 (0.47) | TMPRSS4P2RX1KMT2AKDM4E | |
| Hydrochloric Acid SCHEMBL8102752 | 0.79 | MAPT (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210371403-A1 | SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS | JNANA THERAPEUTICS INC. | 2021-12-02 | — | — | US | disclosed |
| US-20210371403-A1 | SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS | JNANA THERAPEUTICS INC. | 2021-12-02 | — | — | US | disclosed |
| US-20210299070-A1 | METHODS OF TREATING CREATINE TRANSPORTER DEFICIENCY | JNANA THERAPEUTICS INC. | 2021-09-30 | — | — | US | disclosed |
| US-20210299070-A1 | METHODS OF TREATING CREATINE TRANSPORTER DEFICIENCY | JNANA THERAPEUTICS INC. | 2021-09-30 | — | — | US | disclosed |
| WO-2020061473-A1 | SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS | JNANA THERAPEUTICS, INC. (US) | 2020-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210299070-A1 | METHODS OF TREATING CREATINE TRANSPORTER DEFICIENCY | SLC19A1, SLC1A5, SLC1A2 | TMPRSS4 1380/4885NPC1 138/4885CRHBP 642/4885 |
| US-20210371403-A1 | SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS | SNRPE, G3BP1, G3BP2 | TMPRSS4 3136/4885NPC1 947/4885CRHBP 1505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.